Sonoma Pharmaceuticals (NASDAQ:SNOA)‘s stock had its “buy” rating reissued by stock analysts at Maxim Group in a research note issued to investors on Wednesday. They presently have a $7.00 price target on the stock, down from their prior price target of $11.00. Maxim Group’s price objective indicates a potential upside of 56.95% from the stock’s previous close.
SNOA has been the subject of several other research reports. Zacks Investment Research upgraded Sonoma Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.75 target price for the company in a research report on Friday, January 19th. Benchmark initiated coverage on Sonoma Pharmaceuticals in a research report on Thursday, December 28th. They set a “speculative buy” rating and a $10.00 target price for the company.
Sonoma Pharmaceuticals (NASDAQ:SNOA) opened at $4.46 on Wednesday. Sonoma Pharmaceuticals has a 12-month low of $4.16 and a 12-month high of $8.25. The company has a debt-to-equity ratio of 0.01, a quick ratio of 4.56 and a current ratio of 5.37.
About Sonoma Pharmaceuticals
Sonoma Pharmaceuticals, Inc, formerly Oculus Innovative Sciences, Inc, is a specialty pharmaceutical company that develops and markets solutions for the treatment of dermatological conditions and advanced tissue care. The Company’s product portfolio consists of dermatology and advanced tissue care products based upon its technologies, such as Microcyn and Lipogrid.
Receive News & Ratings for Sonoma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sonoma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.